Your latest cannabis business info from Europe

Your latest cannabis business info from Europe


Ukraine: Darnitsa and its cautious approach to cannabis medicines

Ukraine: Darnitsa and its cautious approach to cannabis medicines

The Kyiv-based pharmaceutical company Darnitsa maintains a discreet attitude toward cannabis-based medical goods in Ukraine. Director of medicinal Affairs at Darnitsa, Igor Nykyforchyn, recently discussed the company’s cautious stance and the present state of medicinal cannabis use globally.

Understanding the cannabis market

Research on medical cannabis continues to be of significant interest to pharmaceutical corporations all around the world. Like many other respectable businesses, Darnitsa keeps a close eye on the development of clinical cannabis research in Ukraine. The company wants to assure the safety and effectiveness of cannabis medicinal products, even if there is increasing evidence of its potential medical benefits.

Only four cannabis medications now have the authorisation, according to Nykyforchyn. When conventional therapies are unable to relieve certain illnesses, these drugs can be the alternatives. Nabilone is one of the drugs with the approval. When conventional antiemetic therapy fails to control nausea and vomiting brought on by antitumor chemotherapy, this medication is utilised. Nabiximols is a different one. When conventional treatment approaches fail to control multiple sclerosis’ moderate to severe weakness, it is provided. Additionally, Cannabidiol is used to treat seizures in kids with Lennox-Gastaut syndrome and Dravet syndrome who are two years old and older. Dronabinol is the last substance. When standard therapy fails, this medicine treats nausea in chemotherapy and vomiting in HIV patients with anorexia.

Limitations in case of cannabis medicines

Of course, previously mentioned cannabis-based medications are not the primary treatments for the illnesses listed above. They rather are alternate options. There is currently no approved medication explicitly prescribed for the treatment of pain or post-traumatic stress disorder (PTSD). However there are ongoing discussions regarding the possible uses of medical cannabis. The Darnitsa company stays on a safe side with the introduction of medical cannabis products in Ukraine.

Nykyforchyn emphasised that the American Psychiatric Association opposes the use of medical cannabis to treat post-traumatic stress disorder (PTSD). Additionally, the absence of strong clinical support for novel indications points to the necessity for additional investigation into the benefits and potential hazards of cannabis-based therapies.

Ukraine and its plans to legalize medical cannabis

The Verkhovna Rada in Ukraine has stated a desire to legalise medical cannabis. President Volodymyr Zelenskyy, who supports the potential advantages of medical cannabis for people in need, has spoken out in favour of this choice. To ensure safe and efficient use, additional research and clinical proof are necessary before wide adoption and implementation.

The Darnitsa keeps a cautious approach to cannabis-based medicines. Even though there is an increase in global interest in medical cannabis. The organisation places a high priority on the safety and wellbeing of patients, with only a few certified choices for particular diseases. Finding a balance between innovation and research-based medicine is essential as Ukraine considers the legalisation of medical cannabis. In order to fully understand the potential of medical cannabis and its function in modern healthcare, Ukraine and pharmaceutical companies need more thorough clinical study and testing.


Support for cannabis pilot project in Valais, Switzerland

Cannabis decriminalisation, depenalization, diversion, and legalisation


Sustainability and growth in the hemp&cannabis industry: Synbiotic